Elisabeth Vandenberghe

Elisabeth Vandenberghe


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1999 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
MGMamdooh Gari
Mamdooh Gari
AGAnne Goodeve
Anne Goodeve
GWGill Wilson
Gill Wilson
PWPeter Winship
Peter Winship
SLStephen Langabeer
Stephen Langabeer
JRJohn Reilly
John Reilly
Genomic DNA from 60 cases of acute myeloid leukaemia (AML) was screened for mutations in the c‐kit gene. DNA from all 21 exons was subjected to polymerase chain reaction (PCR) amplification and analysis by conformation sensitive gel electrophoresis (CSGE); exons showing altered CSGE patterns were then sequenced. Mutations were identified only in those patients with inv(16) (3/7 cases) or t(8;21) (1/2 cases) and comprised three in‐frame deletion plus insertion mutations (exon 8) and one point mutation (exon 10, GTA → ATA, Val530Ile). Exons 8 and 10 were then analysed in 31 further cases of inv(16) (n = 14) and t(8;21) (n = 17), revealing four additional exon 8 in‐frame deletion plus insertion mutations, all of which were in cases of inv(16). All exon 8 in‐frame deletion plus insertion mutations (n = 7) involved the loss or repacement of the codon for Asp419 which is highly conserved cross species and is located in the receptor's extracellular domain. The high frequency of the c‐kit proto‐oncogene exon 8 deletion plus insertion mutations in AML suggests an essential role for this region of the receptor's extracellular domain. The association with inv(16) invites speculation as to the link between these two changes in the pathogenesis of AML.

1 October 2000 in British Journal of Haematology
Verified
Journal Article
Closed access
FAF. M. Abu-Duhier
F. M. Abu-Duhier
AGA. C. Goodeve
A. C. Goodeve
GWG. A. Wilson
G. A. Wilson
MGM. A. Gari
M. A. Gari
IPI. R. Peake
I. R. Peake
JRJ. T. Reilly
J. T. Reilly

1 March 2017 in The Lancet Haematology
Verified
Journal Article
Closed access
JJJeffrey A Jones
Jeffrey A Jones
Ewa RobakEwa Robak
Ewa Robak
JBJennifer R Brown
Jennifer R Brown
FAFarrukh T Awan
Farrukh T Awan
XBXavier Badoux
Xavier Badoux
COCarolyn Owen
Carolyn Owen

5 July 2002 in Blood
Verified
Journal Article
Closed access
PDF file
DMDavid I. Marks
David I. Marks
RLRichard Lush
Richard Lush
JCJamie Cavenagh
Jamie Cavenagh
DMDonald W. Milligan
Donald W. Milligan
SSSteven Schey
Steven Schey
CWCatherine D. Williams
Catherine D. Williams
We describe the toxicity and efficacy of donor lymphocyte infusions (DLIs) given to 81 patients (median age, 50 years) after reduced-intensity conditioning (RIC) transplantations performed at 16 centers in the United Kingdom. The diseases treated included non-Hodgkin lymphoma (NHL; n = 29), chronic myeloid leukemia (CML; n = 12), myeloma (n = 11), acute myeloid leukemia (AML; n = 10), and chronic lymphocytic leukemia (CLL; n = 9). Eighty-eight percent received stem cells from sibling donors. The patients received 130 infusions (median, 1; range, 1-4). Indications for DLI were unsatisfactory response/disease progression in 51 patients, mixed chimerism in 18, preemptive in 10, and other in 2. Graft hypoplasia was uncommon (11%). Grade II to IV graft-versus-host disease (GVHD) occurred in 23 of 81 patients (28%) and limited and extensive chronic GVHD in 5 of 69 and 18 of 69 evaluable patients (total incidence 33%). Conversion from mixed to full donor chimerism occurred in 19 of 55 evaluable patients (35%) at a median of 48 days after the DLI; partial responses occurred in 6 patients (total response rate 45%). Eighteen of 51 (35%) patients with measurable disease after stem cell transplantation had a complete response (2 molecular), and 5 a partial response (total response rate 45%). Eleven of 17 evaluable complete responders had full donor chimerism. Eight of 13 patients with follicular NHL had complete responses as did 4 of 12 patients with CML. Clinical and chimeric responses correlated strongly with acute and chronic GVHD. Forty-seven patients (58%) survive at a median of 508 days after transplantation (range, 155-1171 days) with a median Karnofsky score of 90. Thirty-four patients (42%) died at a median of 211 days after transplantation with the major causes being progressive disease (26%) and GVHD (9%). Further systematic studies are required to determine the efficacy and optimum use of DLI for patients with each disease treated by nonmyeloablative stem cell transplantation.

3 March 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
EVElisabeth Vandenberghe
Elisabeth Vandenberghe
CECarmen Ruiz de Elvira
Carmen Ruiz de Elvira
FLFausto R. Loberiza
Fausto R. Loberiza
ECE Conde
E Conde
ALA. López‐Guillermo
A. López‐Guillermo
NSNorbert Schmitz
Norbert Schmitz
Summary. Mantle cell lymphoma (MCL) has an aggressive clinical course with a median survival < 3 years and is incurable with conventional chemotherapy. A large multicentre study with adequate follow‐up may clarify the role of significant factors affecting outcome in autologous stem cell transplantation for MCL. Patients receiving an autologous transplant for MCL between 1988 and 1998, and reported to the European Blood and bone Marrow Transplant (EBMT) registry or Autologous Blood and Marrow Transplant Registry (ABMTR), were included. Expert haematopathology review was required on all identified patients. Disease and transplant details were requested from the transplant centres, and the final cohort of patients with verified pathology, adequate clinical information and follow‐up was analysed. One hundred and ninety‐five patients were included in the analyses (149 EBMT, 46 ABMTR) with a median follow‐up of 3·9 years. The 2 year and 5 year overall survival were 76% and 50%, and progression free survival was 55% and 33% respectively. Disease status at transplant was the most significant factor affecting survival: patients with chemosensitive disease but not in first complete remission (CR1) were 2·99 times (95% CI: 1·66–5·38, P < 0·001) more likely to die than patients transplanted in CR1. Autologous transplantation probably improves survival in patients with MCL especially if performed in first CR.

1 January 1991 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
EVElisabeth Vandenberghe
Elisabeth Vandenberghe
CWChris De Wolf‐Peeters
Chris De Wolf‐Peeters
JOJoost Van Den Oord
Joost Van Den Oord
IWIvonna Wlodarska
Ivonna Wlodarska
JDJan Delabie
Jan Delabie
HBHerman Van Den Berghe
Herman Van Den Berghe